NCT07844512RecruitingPhase 3
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tapentadol in Patients Undergoing Bariatric Surgery
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine. Eligible patients having bariatric surgery will be randomly assigned to one of the two treatment groups. Patients and study teams will not know which treatment each participant receives. Participants will be grouped based on whether they have obstructive sleep apnea (OSA). The primary measurement is postoperative recovery quality in the first 24 hours after surgery using the QoR-15 survey. The study will also track pain scores, rescue pain medication use, and drug side effects for 7 days after surgery. There is no guaranteed benefit for participants. Study pain medicines may cause side effects. Doctors will provide rescue treatment for uncontrolled pain.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 148 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 28 Oct 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- The First Hospital of Jilin University
- Diseases
- Obesity
- NCT number
- NCT07844512
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 148
- From 28 Oct 2026 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another interventional clinical trial within 30 days before surgery
Other illness
- Known allergy or hypersensitivity to opioids, tegileridine or sufentanil
- History of severe respiratory disease except obstructive sleep apnea
Other
- Severe hepatic or renal dysfunction
- Preoperative chronic opioid use
- Pregnant or breastfeeding women
- Participants who cannot complete postoperative follow-up
Who the study is looking for
- Age 18 to 65 years old
- Scheduled for elective bariatric surgery
- American Society of Anesthesiologists (ASA) physical status I, II or III
- Able to understand and complete the QoR-15 questionnaire
- Provide written informed consent to participate in the study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.